JUL 17, 2017 6:48 PM PDT

Putting A Target On Cancer's Back

WRITTEN BY: Kara Marker

Scientists are putting a target on cancer’s back, and immune cells are being trained to track down and kill that target. In a new study from the University of Texas M.D. Anderson Cancer Center, researchers describe how they used immune cells acquired from donated umbilical cord blood to be trained and suited up to identify leukemia and lymphoma cancer cells.

 

A Wright's stained peripheral blood smear showing chronic lymphocytic leukemia (CLL). The lymphocytes with the darkly staining nuclei and scant cytoplasm are the CLL cells.

 

Natural killer (NK) cells derived from cord blood are capable of targeting cancer on their own, but a new method of modifying these cells makes them even better at getting the job done. First, they are genetically engineered to be particularly persistent on finding and killing cancer. Lacing their genome with an immune chemical called interleukin (IL) 15 accomplishes this.

Next, a chimeric antigen receptor (CAR) focuses NK cells on B cell malignancies, such as surface protein CD19. This, says study researcher Elizabeth Shpall, MD, turns the NK cells into “guided missiles.” Lastly, researchers included a “self-destruct gene,” installed to protect already-weakened cancer patients against an excessive inflammatory response.

Results from studies in cell lines and mouse model showed that the modified NK cells destroyed tumors better and longer than normal NK cells. A unique phase I/II human clinical trial for patients with relapsed or resistant B cell cancers, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), and non-Hodgkin lymphoma, began in June. Scientists will assess the potential of the newly modified NK cells in the setting of human cancer, the ultimate test.

"Natural killer cells are the immune system's most potent killers, but they are short-lived and cancers manage to evade a patient's own NK cells to progress," explained Katy Rezvani, MD, PhD. "Our cord-blood derived NK cells… are designed to address these challenges.” Indeed, Rezvani’s modified NK cells have been shown to persist for months instead of just a few weeks.

Benefits of using this approach in NK cells versus T cells

There is a risk of graft versus host disease in CAR T cells if cells are taken from a donor. T cells can be taken from the patient, but the process of transforming them into CAR T cells takes several weeks. So far, CAR NK cells from donated cord blood have shown no risk of graft versus host disease.

The MD Anderson Cord Blood Bank, found and directed by Shpall, now has 26,000 cords stored. The present study was published in the journal Leukemia.

Sources: University of Texas M.D. Anderson Cancer Center, Nature Immunology

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
DEC 06, 2019
Health & Medicine
DEC 06, 2019
Study finds association between hair products and breast cancer risk
For many women, hair color and style are significant components of their identity. However, troubling information from a new study about the use of hair dy...
DEC 24, 2019
Cancer
DEC 24, 2019
The effect of aspirin on breast cancer
New research published recently in the journal Cancer aims to better understand the effects that aspirin can have on breast cancer. Previous research has s...
JAN 07, 2020
Clinical & Molecular DX
JAN 07, 2020
Saliva Test for Early Detection of Mouth and Throat Cancer
“OPC is one of the fastest rising cancers in Western countries due to increasing HPV-related incidence, especially in younger patients. It is paramou...
JAN 13, 2020
Cancer
JAN 13, 2020
The anti-cancer properties of bitter melon
New research published in the journal Cell Communication and Signaling suggests that bitter melon, also known as bitter gourd, may have anti-cancer propert...
FEB 10, 2020
Immunology
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
Loading Comments...